# Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

Study · id `cardio:ct-nct03058029` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03058029](<https://clinicaltrials.gov/study/NCT03058029>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03058029

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT03058029. Randomized; triple masking; primary purpose treatment. Start 2017-02-22 (actual); primary completion 2021-01-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT03058029, source copy `cardio:ctgov-nct03058029-2020-07-21`, retrieved 2026-11-18)
- Started: 2017-02-22 (actual) (ClinicalTrials.gov record NCT03058029, source copy `cardio:ctgov-nct03058029-2020-07-21`, retrieved 2026-11-18)
- Primary completion: 2021-01-15 (anticipated) (ClinicalTrials.gov record NCT03058029, source copy `cardio:ctgov-nct03058029-2020-07-21`, retrieved 2026-11-18)
- Completion: 2021-01-15 (anticipated) (ClinicalTrials.gov record NCT03058029, source copy `cardio:ctgov-nct03058029-2020-07-21`, retrieved 2026-11-18)
- Countries: United States; Canada; Czechia; Denmark; Hungary; Italy; Poland; United Kingdom (ClinicalTrials.gov record NCT03058029, source copy `cardio:ctgov-nct03058029-2020-07-21`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03058029-2020-07-21`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
- Acronym: LIGHT-UP
- Condition: Overweight
- Condition: Diabetes
- Condition: PreDiabetes
- Condition: Obesity
- Intervention (Device): Gelesis200
- Intervention (Device): Placebo
- Lead sponsor: Gelesis, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)

## Provenance

Content hash: d348528e774d5e757fee44dbd6aa2af078d9b41d180ea90e70b254c89fd262a6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
